Signal active
Bio
Cameron is a Principal on the Private Transactions team at Deerfield. Cameron joined Deerfield in 2014 and focuses on therapeutics companies. Prior to joining Deerfield, Cameron was at Eleven Biotherapeutics for more than five years, where he was responsible for corporate development and commercial strategy. He was instrumental in the founding, building, and the eventual public offering of Eleven Biotherapeutics. Prior to Eleven, Cameron was at Third Rock Ventures, a Boston-based venture capital firm focused on launching and building life science companies. While at Third Rock, Cameron gained business development and operating experience as a member of the founding team of Constellation Pharmaceuticals. Cameron holds a Ph.D. and S.M. in Biological Engineering and an S.B. in Mechanical Engineering from Massachusetts Institute of Technology.
Location
New York, New York, United States, North America
Social
Primary Organization
1994
271
143
128
101-250
Financial Services, Venture Capital, Impact Investing, Hedge Funds
Jobs history
2
Vicinitas Therapeutics
Board Member
2022 - Current
Nuvalent
Board Member
Invalid date - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Cameron Wheeler is the Principal at Deerfield, based in New York, New York, United States, North America. With a background in Financial Services, Cameron Wheeler has a rich history of leadership and innovation. Cameron Wheeler studied Ph.D Biological Engineering @ Massachusetts Institute of Technology. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
12
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
May 11, 2021 | Nuvalent | Series B - Nuvalent | Deerfield | 135.0M |
Jun 14, 2021 | Ribon Therapeutics | Series C - Ribon Therapeutics | Deerfield | 65.0M |
Jul 28, 2022 | Vicinitas Therapeutics | Series A - Vicinitas Therapeutics | Deerfield | 65.0M |
Jan 05, 2023 | Perceive Biotherapeutics | Series B - Perceive Biotherapeutics | Deerfield | 78.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.